Skip to main content


Advancing Health Equity Through Diversity

Published April 29th, 2022

PHM are experts in helping patients overcome barriers to clinical trial access and enrollment, and we applaud the recent draft guidance released by the U.S. Food and Drug Administration (FDA) to make clinical trials more representative and inclusive for underrepresented racial and ethnic communities. PHM also wholeheartedly supports the Biden-Harris Administration’s Cancer Moonshot goal of addressing inequities in cancer care, helping to ensure that every community in America has access to cutting-edge cancer diagnostics, therapeutics and clinical trials. We look forward to advancing this work and helping to make clinical trials accessible to everyone who needs them.